Intellia Therapeutics Inc
NASDAQ:NTLA

Watchlist Manager
Intellia Therapeutics Inc Logo
Intellia Therapeutics Inc
NASDAQ:NTLA
Watchlist
Price: 10.62 USD 4.89% Market Closed
Market Cap: 1.1B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+17%
Revenue
Forecast
-3%
Operating Income
Forecast
N/A
Net Income
Forecast
-2%

Wall Street
Price Targets

NTLA Price Targets Summary
Intellia Therapeutics Inc

Wall Street analysts forecast NTLA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NTLA is 33.84 USD with a low forecast of 7.07 USD and a high forecast of 111.3 USD.

NTLA Lowest Forecast
Wall Street Target
7.07 USD
33% Downside
NTLA Average Forecast
Wall Street Target
33.84 USD
219% Upside
NTLA Highest Forecast
Wall Street Target
111.3 USD
948% Upside
Lowest
Price Target
7.07 USD
33% Downside
Average
Price Target
33.84 USD
219% Upside
Highest
Price Target
111.3 USD
948% Upside
Intellia Therapeutics Inc Competitors:
Price Targets
SBTX
SkinBioTherapeutics PLC
104% Upside
ALGEN
Genoway SA
96% Upside
SLNO
Soleno Therapeutics Inc
75% Upside
BVXP
Bioventix PLC
87% Upside
SBTX
SkinBioTherapeutics PLC
104% Upside
ALGEN
Genoway SA
96% Upside
SLNO
Soleno Therapeutics Inc
75% Upside
BVXP
Bioventix PLC
87% Upside
4
4BB
4Basebio PLC
96% Upside
2171
CARsgen Therapeutics Holdings Ltd
10% Upside
B
2480
Beijing Luzhu Biotechnology Co Ltd
27% Upside
B
BAVA
Bavarian Nordic A/S
15% Upside

Revenue
Forecast

Revenue Estimate
Intellia Therapeutics Inc

For the last 9 years the compound annual growth rate for Intellia Therapeutics Inc's revenue is 29%. The projected CAGR for the next 3 years is 7%.

29%
Past Growth
7%
Estimated Growth
Estimates Accuracy
-5%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Intellia Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Intellia Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-44%
Average Miss
What are analyst estimates?

See Also

Summary
NTLA intrinsic value, competitors valuation, and company profile.
DCF Valuation
NTLA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NTLA stock valuation using valuation multiples.
Wall Street Estimates
NTLA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NTLA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NTLA's stock price target?
Price Target
33.84 USD

According to Wall Street analysts, the average 1-year price target for NTLA is 33.84 USD with a low forecast of 7.07 USD and a high forecast of 111.3 USD.

What is Intellia Therapeutics Inc's Revenue forecast?
Projected CAGR
7%

For the last 9 years the compound annual growth rate for Intellia Therapeutics Inc's revenue is 29%. The projected CAGR for the next 3 years is 7%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 277,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.